Protein Chemistry and Enzyme Technology, Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads 221, 2800 Kgs, Lyngby, Denmark.
Protein Chemistry and Enzyme Technology, Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads 221, 2800 Kgs, Lyngby, Denmark.
Carbohydr Res. 2020 Jul;493:108029. doi: 10.1016/j.carres.2020.108029. Epub 2020 May 8.
Human milk oligosaccharides (HMOs) are a family of structurally distinct carbohydrate oligomers present in human milk. HMOs protect breastfed babies against infection and promote the development of infant health and cognition. In the gut, fucosylated HMOs in particular function as decoy receptors that intercept epithelial attachment of enteric pathogens and hence help reduce infection. Infant formulae made from bovine milk are essentially devoid of HMOs, which creates a large impetus for biosynthetic production of HMOs. Certain microbial α-L-fucosidases (EC 3.2.1.51, EC 3.2.1.111), specifically various retaining α-L-fucosidases of glycoside hydrolase family 29 (GH29), are capable of catalysing transfucosylation. The use of GH29 α-L-fucosidases to promote transfucosylation reactions thus represents a strategy for biocatalytic synthesis of fucosylated HMOs. The purpose of this review is to present the current knowledge on the use of such α-L-fucosidases for synthesis of fucosylated HMOs by enzymatic transfucosylation. We summarize the available data obtained for both wild type and engineered microbial α-L-fucosidases, discuss enzyme and substrate sources, and review factors governing transglycosylation performance, particularly the use of protein engineering. We describe the mechanistic reaction details of α-l-fucosidase transfucosylation, and examine details of enzyme mutation strategies promoting transfucosylation. Finally, we list recommendations for future reaction targets based on currently abundant substrate sources.
人乳寡糖(HMOs)是存在于人乳中的一组结构不同的碳水化合物低聚糖。HMOs 可保护母乳喂养的婴儿免受感染,并促进婴儿健康和认知的发展。在肠道中,特别地,岩藻糖基化的 HMOs 作为诱饵受体发挥作用,可拦截肠病原体对上皮细胞的附着,从而有助于减少感染。由牛乳制成的婴儿配方奶粉基本上不含 HMOs,这为 HMOs 的生物合成生产创造了巨大的动力。某些微生物 α-L-岩藻糖苷酶(EC 3.2.1.51、EC 3.2.1.111),特别是糖苷水解酶家族 29(GH29)的各种保留 α-L-岩藻糖苷酶,能够催化转岩藻糖基化。因此,使用 GH29 α-L-岩藻糖苷酶来促进转岩藻糖基化反应代表了生物催化合成岩藻糖基化 HMOs 的策略。本综述的目的是介绍目前关于使用这些 α-L-岩藻糖苷酶通过酶促转岩藻糖基化合成岩藻糖基化 HMOs 的知识。我们总结了获得的野生型和工程化微生物 α-L-岩藻糖苷酶的可用数据,讨论了酶和底物来源,并回顾了控制转糖基化性能的因素,特别是使用蛋白质工程。我们描述了 α-L-岩藻糖苷酶转岩藻糖基化的反应细节,并检查了促进转岩藻糖基化的酶突变策略的细节。最后,我们根据目前丰富的底物来源列出了未来反应目标的建议。